Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews

Potential Adverse Events Reported With the Janus Kinase Inhibitors Approved for the Treatment of Rheumatoid Arthritis Using Spontaneous Reports and Online Patient Reviews

The aim of this study was to analyze the potential adverse events (AEs) caused by Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, and upadacitinib, used to treat rheumatoid arthritis using spontaneous AE reports from the FDA (FAERS) and interpreting them in correlation with those...

Full description

Bibliographic Details
Main Authors:	Yun-Kyoung Song, Junu Song, Kyungim Kim, Jin-Won Kwon
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-01-01
Series:	Frontiers in Pharmacology
Subjects:	Janus kinase inhibitors rheumatoid arthritis adverse event reporting systems online patient reviews potential adverse events
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.792877/full

Similar Items

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and metaanalysis of clinical trial studies
by: Amal Saki, et al.
Published: (2021-07-01)

Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
by: Qige Wei, et al.
Published: (2023-08-01)

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024-12-01)

Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
by: Huibin Yang, et al.
Published: (2025-12-01)

Performance of Cardiovascular Risk Prediction Models in Korean Patients With New‐Onset Rheumatoid Arthritis: National Cohort Study
by: Jae Hyun Kim, et al.
Published: (2023-11-01)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
by: Han N, et al.
Published: (2021-08-01)

Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis
by: Chuen-Huei Liu, et al.
Published: (2024-09-01)

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
by: Xianglin Pan, et al.
Published: (2024-07-01)

Three aspects of acupuncture-related adverse events: Issues around the reporting of acupuncture-related adverse events
by: Tae-Hun Kim, et al.
Published: (2023-09-01)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
by: Hou H, et al.
Published: (2019-05-01)

Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis
by: Ji-Won Kim, et al.
Published: (2021-10-01)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
by: Xiaojiang Tian, et al.
Published: (2022-03-01)

The Risk of Adverse Effects of TNF-α Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis
by: Bei He, et al.
Published: (2022-02-01)

Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015–2019
by: Kyung-In Joung
Published: (2023-11-01)

Use of Janus kinase inhibitors in the treatment of immunoinflammatory rheumatic diseases: safety issues
by: B. S. Belov, et al.
Published: (2021-03-01)

Treatment interruption of biological drugs and tofacitinib in rheumatoid arthritis: A systematic review of case reports
by: Astrid Wiens, et al.
Published: (2019-04-01)

JAK inhibitors for the treatment of rheumatoid arthritis
by: Akio Morinobu
Published: (2020-10-01)

Prevalence rate of spontaneously reported adverse events and determinants of serious adverse events amongst three outpatient care settings in ghana: findings and implications
by: Israel Abebrese Sefah, et al.
Published: (2021-01-01)

The reaction of the skin and its appendages in rheumatoid arthritis patients using subcutaneous methotrexate: A description of three cases
by: Yu. V. Muravyev, et al.
Published: (2016-10-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
by: Elizabeth C. James, et al.
Published: (2020-09-01)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
by: Xue-Feng Jiao, et al.
Published: (2023-01-01)

Progressive multifocal leukoencephalopathy reports in rheumatoid arthritis concerning different treatment patterns-an exploratory assessment using the food and drug administration adverse event reporting system
by: Takeshi Honma, et al.
Published: (2024-05-01)

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS
by: Ganggang Wang, et al.
Published: (2025-01-01)

Adverse events: an expensive and avoidable hospital problem
by: Diego San Jose-Saras, et al.
Published: (2022-12-01)

RUSSIAN AND INTERNATIONAL EXPERIENCE IN THE APPLICATION OF THE JANUS-KINASES INHIBITOR IN RHEUMATOID ARTHRITIS
by: D. E. Karateev, et al.
Published: (2017-05-01)

Publication status and reporting quality of case reports on acupuncture-related adverse events: A systematic reviews of case studies
by: Tae-Hun Kim, et al.
Published: (2023-10-01)

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
by: Yun-Kyoung Song, et al.
Published: (2023-10-01)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
by: Xusheng Zhang, et al.
Published: (2024-07-01)

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database
by: Yichun Shuai, et al.
Published: (2024-08-01)

Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics
by: Oh Chan Kwon, et al.
Published: (2024-04-01)

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review
by: Ammar Haikal, et al.
Published: (2018-01-01)

Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
by: Jinfeng Zhu, et al.
Published: (2024-07-01)

SAFETY OF USING METHOTREXATE SOLUTION FOR SUBCUTANEOUS INJECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: Yu. V. Muravyev, et al.
Published: (2015-09-01)

Adverse Event Profiles of the Third-Generation Aromatase Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
by: Yina Zhang, et al.
Published: (2024-08-01)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor
by: Yunyan Pan, et al.
Published: (2024-04-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events
by: Stephanie L. Gu, et al.
Published: (2023-11-01)